Fairbanks has successfully met all SBIR Phase I milestones and has submitted a Phase II application to focus on in vivo therapeutic benefits.
Fairbanks Pharmaceuticals Inc was selected as a semi-finalist in the competition for MilliporeSigma’s Start-Up program at LabCentral in Cambridge MA. The winner will be awarded a “Golden Ticket” of 1 year of space at one of the country’s leading and highly desirable biotechnology incubators, a fantastic opportunity to move to an environment that fosters partnerships and collaborations that can accelerate our therapeutic development activities.
On August 1, Dr. Alan Schneyer, Fairbanks Co-Founder and CEO, presented Fairbanks’ plans and progress to a highly selective board of judges composed of MilliporeSigma scientists and Lab Central Senior Managers. Results of the judges decision will be announced in mid-August.
Fairbanks Pharmaceuticals presented its unique and innovative approach to attacking the underlying pathology of diabetes by increasing insulin production from existing beta cells and simultaneously inducing regeneration of beta cells at the MassCONNECT Final Showcase on May 18th 2017. The presentation was met with widespread interest from both pharma and private investors.
The Final Showcase was the culmination of an eight-week mentorship program with a team of biotech and pharmaceutical industry leaders to help with strategic planning, identifying potential partners and financing, and developing a slide deck.
In this picture, featured in the Boston Globe, Alan sports a sign about the benefits of scientific research.
Fairbanks was selected to present at UMass’ Technology Transfer Center’s Early-Stage Life Sciences Technology Conference on April 5, 2017. The presentation will focus on our technology, IP, potential markets, sustainable competitive advantage, developmental stage, and future plans. Stay tuned for a release of our latest slide deck.
Alan Schneyer and Elissa Brown gave Fairbanks’ introductory pitch today to MassBio’s 2017 Cycle 1 MassConnect mentors. Fairbanks was one of four biotech startups selected by MassBio to join the only entrepreneur mentorship program in Massachusetts that dives deep into the life sciences. MassCONNECT matches entrepreneurs and founders with seasoned life sciences professionals to catalyze and commercialize innovation.
The MassCONNECT process involves a two-month mentorship where industry experts guide entrepreneurs as they seek to develop business plans, launch companies, and raise capital.
MassCONNECT mentors evaluate and provide feedback on commercial feasibility; identify strengths, weaknesses, opportunities and threats; and team up to furnish industry-specific business advice for innovative ideas in therapeutics, diagnostics, medical devices and health IT. Entrepreneurs gain invaluable advice and coaching on defining value proposition, developing pitches and building professional networks.
Click here for more information on today’s kick-off.
(December 2016) Boehringer-Ingelheim Pharmaceuticals (BI) selected Fairbanks from 30 applicants to compete for their Boston Innovation Prize. BI runs this competition to help sustain innovative pipelines for new breakthrough therapies by providing a Golden Ticket for Lab Central space (valued at $75,000) in Cambridge, MA. The panel of judges includes senior and founding members of Lab Central and BI’s venture capital fund, as well as other seed stage investor groups.
We’re growing! Fairbanks Pharmaceuticals is now Fairbanks Pharmaceuticals, Inc., incorporated in the state of Delaware and registered in the Commonwealth of Massachusetts.
Fairbanks Pharmaceuticals was awarded a pilot grant from the UMass Office of the President’s Science and Technology Fund to screen small molecules with the goal of identifying compounds that will promote the transdifferentiation of pancreatic alpha cells into insulin secreting beta cells.
This highly competitive funding program was created by UMass to stimulate the development of high impact therapeutic candidates. Proposals were selected based on assay feasibility, medical relevance, and commercialization potential.